Dynavax Technologies said on Thursday its experimental shingles vaccine generated a similar immune response as GSK's blockbuster shot Shingrix, while showing a better safety profile, in an ...

Dynavax Technologies Corp. (DVAX) on Thursday said that its experimental Shingles vaccine yielded positive results in an ...

Dynavax (DVAX) stock gains as the company's Z-1018 shingles shot shows immune response comparable to GSK's (GSK) Shingrix vaccine in a Phase 1/2 trial. Read more here.

Shares of Dynavax rose after the company released positive results from a trial of its shingles vaccine tested against current Shingles vaccine Shingrix. The stock was up 6.7% to $11.12 but is still ...

Dynavax's Z-1018 shingles vaccine matched Shingrix in immune response with fewer side effects, advancing to Phase 2 in older adults in 2025.

Dynavax’s lofty ambition to snatch Shingrix’s crown got off to a promising start after the biopharma’s investigational shingles vaccine held its own against GSK’s mainstay in the first part of a phase ...

Investing.com -- Dynavax Technologies Corporation (NASDAQ: DVAX) stock soared 8% Thursday after the company announced positive topline results from its Phase 1/2 clinical trial for Z-1018, its ...

Dynavax is advancing CpG 1018 as a premier vaccine adjuvant used in clinical programs for shingles and Tdap, and in global collaborations currently focused on adjuvanted vaccines for COVID-19 ...

Dynavax is advancing CpG 1018 as a premier vaccine adjuvant used in clinical programs for shingles and Tdap, and in global collaborations currently focused on adjuvanted vaccines for COVID-19 ...

Record HEPLISAV-B® quarterly net product revenue of $92 million, representing 31% year-over-year growth Refines full year 2025 HEPLISAV-B net product revenue guidance ...

Dynavax’s HEPLISAV-B revenue hit $268M in 2024, up 26% YoY, with Q4 revenue at $71M, up 39%. Analysts project Dynavax’s 2024 sales at $278.13M, with Q4 EPS at $0.04 and revenue of $72.92M. 9 ...

Dynavax is advancing CpG 1018 as a premier vaccine adjuvant used in clinical programs for shingles and Tdap, and in global collaborations currently focused on adjuvanted vaccines for COVID-19 ...